Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Galapagos Signs Two Drug Discovery Collaborations with Ono

  • Galapagos’ BioFocus DPI service division has signed two collaborations with Ono Pharmaceutical Company. "The new contracts show the benefit of building a global drug discovery service business," says Onno van de Stolpe, CEO of Galapagos. “We combine expertise from our acquired companies Discovery Partners International, BioFocus, as well as Inpharmatica, realizing the synergy in bringing these activities together.”

     

    Under the first collaboration, BioFocus DPI will use selected compounds from its SoftFocus and other synthetic small molecule collections to perform high-throughput screening for Ono's drug discovery program.

     

    In the second deal, BioFocus DPI will apply its medicinal and computational chemistry and ADME profiling expertise in multiple medicinal chemistry projects for Ono.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »